HBIO Harvard Bioscience Inc.

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024

HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.

The Company’s presentation is scheduled for 2:45-3:20 PM ET on June 12th. The Company will also host one-on-one investor meetings throughout the day. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website at . A replay will be available shortly after the presentation has concluded. To schedule a one-on-one meeting, please contact the Three Part Advisors conference team at (817) 769-2373 or .

About Harvard Bioscience, Inc.  

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.  

For more information, please visit our website at .

Company Contact:

Harvard Bioscience

Jennifer Cote, Chief Financial Officer

(508) 893-3120

Investor Contacts:

Three Part Advisors

Sandy Martin / Erol Girgin / William Shelmire



(214) 616-2207



EN
06/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE

Harvard Bioscience Appoints John Duke to Board of Directors

Harvard Bioscience Appoints John Duke to Board of Directors HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. “We are pleased to welcome John to Harvard Bioscience’s board,” said Katherine Eade, Lead Independent Director. “John brings ...

 PRESS RELEASE

Harvard Bioscience Announces First Quarter 2025 Financial Results

Harvard Bioscience Announces First Quarter 2025 Financial Results HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China.” We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid syst...

 PRESS RELEASE

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Ca...

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the ...

 PRESS RELEASE

Harvard Bioscience Announces CFO Transition

Harvard Bioscience Announces CFO Transition HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation. Mr. Frost brings over 30 years of financial and...

 PRESS RELEASE

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in...

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch